Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recifercept - Pfizer

Next Previous
X
Search
Drug Profile

Recifercept - Pfizer

Alternative Names: PF-07256472; Reciferecept; TA-46

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therachon
  • Developer Pfizer
  • Class Proteins; Recombinant proteins
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Achondroplasia

Most Recent Events

  • 18 Apr 2023 Pfizer withdraws a phase I trial in healthy adult volunteers in China (SC) before enrolment due to corporate strategic considerations (NCT05061277)
  • 27 Mar 2023 Pfizer terminates a phase II trial in Achondroplasia (In infants, In children) in US, Australia, Belgium, Denmark, Italy, Japan, Portugal and Spain (SC), due to lack of efficacy at any of the tested doses(NCT04638153)
  • 03 Feb 2023 Discontinued - Phase-II for Achondroplasia (In children, In infants) in Japan, Italy, USA, Australia (SC) (Pfizer pipeline, February 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top